Solid lipid microparticles for the stability enhancement of a dopamine prodrug

Journal of Pharmaceutical Sciences

Volumn 99, Issue 11, 2010, Pages 4730-4737

  Dalpiaz, Alessandro ^a   Cacciari, Barbara ^a   Mezzena, Matteo ^a   Strada, Mariangela ^a   Scalia, Santo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Controlled release; Dopamine; Microencapsulation; Microparticles; Prodrugs; Solid lipid microparticles; Stabilization

Indexed keywords

3,4 O DIVALEROYLDOPAMINE; DOPAMINE; ESTER; PRODRUG; TRISTEARIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG HYDROLYSIS; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; EMULSION; ENCAPSULATION; HUMAN; PARTICLE SIZE; SLOW DRUG RELEASE;

EID: 78149302578     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22178     Document Type: Article

References (25)

1. Bernheimer H, Birkmayer W, Hornykievicz O, Jellinger K, Seitelberg F. 1973. Brain dopamine and syndromes of Parkinson and Huntington. J Neurol Sci 20: 415-455.
2. Jankovic JJ. 2002. Therapeutic strategies in Parkinson's disease. In: Jankovic JJ, Tolosa E, editors. Parkinson's disease and movement disorders. Philadelphia: Lippincott Williams & Wilkins, pp 116-151.
3. Standaert D, Young A. 1996. Treatment of central nervous system degenerative disorders. In: Gilman AG, Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, editors. The pharmacological basis of therapeutics. New York: McGraw Hill, pp 503-519.
4. Dalpiaz A, Scatturin A, Pavan B, Biondi C, Vandelli MA, Forni F. 2001. Poly (D, L-lactic) acid microspheres for the sustained release of adenosine derivatives with antiischemic properties. J Control Release 73: 303-313.
5. Dalpiaz A, Scatturin A, Pavan B, Biondi C, Vandelli MA, Forni F. 2002. Poly (lactic acid) microspheres for the sustained release of antiischemic agents. Int J Pharm 242: 115-120.
6. Dalpiaz A, Mezzena M, Scatturin A, Scalia S. 2008. Solid lipid microparticles for the stability enhancement of the polar drug N(6)-cyclopentyladenosine. Int J Pharm 355: 81-86.
7. Dalpiaz A, Gavini E, Colombo G, Russo P, Bortolotti F, Ferraro L, Tanganelli S, Scatturin A, Menegatti E, Giunchedi P. 2008. Brain uptake of an antiischemic agent by nasal administration of microparticles. J Pharm Sci (US) 97: 4889-4903.
8. Jaspart S, Piel G, Delattre L, Evrard B. 2005. Solid lipid microparticles: Formulation, preparation, characterization, drug release and applications. Expert Opin Drug Deliv 2: 75-87.
9. Scalia S, Tursilli R, Sala N, Iannuccelli V. 2006. Encapsulation in lipospheres of the complex between butyl methoxydibenzoylmethane and hydroxypropyl-β-cyclodextrin. Int J Pharm 320: 79-85.
10. 2A adenosine receptor antagonists. J Med Chem 41: 2126-2133.
11. Casagrande C, Santangelo F, Saini C, Doggi F, Gerli F, Cerri O. 1986. Synthesis and chemical properties of ibopamine and of related esters of N-substituted dopamines-Synthesis of ibopamine metabolites. Arzneim Forsch/Drug Res 36: 291-303.
12. Borgman RJ, McPhillips JJ, Stitzel RE, Goodman IJ. 1973. Synthesis and pharmacology of centrally acting dopamine derivates and analogs in relation to Parkinson's disease. J Med Chem 16: 630-633.
13. Boomsma F, Alberts G, van Eijk LJ, Man in't Veld A, Schalekamp MA. 1993. Optimal collection and storage conditions for catecholamine measurements in human plasma and urine. Clin Chem 39: 2503-2508.
14. Weir TB, Smith CCT, Round JM, Betteridge DJ. 1986. Stability of catecholamines in whole blood, plasma and platelets. Clin Chem 32: 882-883.
15. Rumley AG. 1988. The in vitro stability of catecholamines in whole blood. Ann Clin Biochem 25: 585-586.
16. 1 receptor agonist. Pharm Res 18: 531-536.
17. Immordino ML, Brusa P, Rocco F, Arpicco S, Ceruti M, Cattel L. 2004. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release 100: 331-346.
18. Castelli F, Sarpietro MG, Rocco F, Ceruti M, Cattel L. 2007. Interaction of lipophilic gemcitabine prodrugs with biomembrane models studied by Langmuir-Blodgett technique. J Colloid Interface Sci 313: 363-368.
19. Olbrich C, Kayser O, Müller RH. 2002. Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)-Effect of surfactants, storage time and crystallinity. Int J Pharm 237: 119-128.
20. Menhert W, Mader K. 2001. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 47: 165-196.
21. Dahlin M, Bergman U, Jansson B, Bjork E, Brittebo E. 2000. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res 17: 737-742.
22. Dahlin M, Jansson B, Bjork E. 2001. Levels of dopamine in blood and brain following nasal administration to rats. Eur J Pharm Sci 14: 75-80.
23. Leher CM, Bouwstra JA, Schacht EH, Junginger H. 1992. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 78: 43-48.
24. Charlton ST, Davis SS, Illum L. 2007. Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: In vitro characterisation studies. J Control Release 118: 225-234.
25. Pavan B, Dalpiaz A, Ciliberti N, Biondi C, Manfredini S, Vertuani S. 2008. Progress in drug delivery to the central nervous system by the prodrug approach. Molecules 13: 1035-1065.